187 related articles for article (PubMed ID: 17200713)
1. Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing.
Mahley RW; Huang Y
J Clin Invest; 2007 Jan; 117(1):94-8. PubMed ID: 17200713
[TBL] [Abstract][Full Text] [Related]
2. Hepatic remnant lipoprotein clearance by heparan sulfate proteoglycans and low-density lipoprotein receptors depend on dietary conditions in mice.
Foley EM; Gordts PLSM; Stanford KI; Gonzales JC; Lawrence R; Stoddard N; Esko JD
Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2065-74. PubMed ID: 23846497
[TBL] [Abstract][Full Text] [Related]
3. Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members.
MacArthur JM; Bishop JR; Stanford KI; Wang L; Bensadoun A; Witztum JL; Esko JD
J Clin Invest; 2007 Jan; 117(1):153-64. PubMed ID: 17200715
[TBL] [Abstract][Full Text] [Related]
4. Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans.
Ji ZS; Sanan DA; Mahley RW
J Lipid Res; 1995 Mar; 36(3):583-92. PubMed ID: 7539827
[TBL] [Abstract][Full Text] [Related]
5. Remnant lipoproteins inhibit malaria sporozoite invasion of hepatocytes.
Sinnis P; Willnow TE; Briones MR; Herz J; Nussenzweig V
J Exp Med; 1996 Sep; 184(3):945-54. PubMed ID: 9064354
[TBL] [Abstract][Full Text] [Related]
6. Disruption of LDL but not VLDL clearance in autosomal recessive hypercholesterolemia.
Jones C; Garuti R; Michaely P; Li WP; Maeda N; Cohen JC; Herz J; Hobbs HH
J Clin Invest; 2007 Jan; 117(1):165-74. PubMed ID: 17200716
[TBL] [Abstract][Full Text] [Related]
7. Hepatic heparan sulfate proteoglycans and endocytic clearance of triglyceride-rich lipoproteins.
Foley EM; Esko JD
Prog Mol Biol Transl Sci; 2010; 93():213-33. PubMed ID: 20807647
[TBL] [Abstract][Full Text] [Related]
8. An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo.
Devlin CM; Lee SJ; Kuriakose G; Spencer C; Becker L; Grosskopf I; Ko C; Huang LS; Koschinsky ML; Cooper AD; Tabas I
Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1704-10. PubMed ID: 15905467
[TBL] [Abstract][Full Text] [Related]
9. Heparan sulfate proteoglycan-mediated uptake of apolipoprotein E-triglyceride-rich lipoprotein particles: a major pathway at physiological particle concentrations.
Al-Haideri M; Goldberg IJ; Galeano NF; Gleeson A; Vogel T; Gorecki M; Sturley SL; Deckelbaum RJ
Biochemistry; 1997 Oct; 36(42):12766-72. PubMed ID: 9335533
[TBL] [Abstract][Full Text] [Related]
10. LDL receptor-related protein mediates cell-surface clustering and hepatic sequestration of chylomicron remnants in LDLR-deficient mice.
Yu KC; Chen W; Cooper AD
J Clin Invest; 2001 Jun; 107(11):1387-94. PubMed ID: 11390420
[TBL] [Abstract][Full Text] [Related]
11. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E.
Mahley RW; Ji ZS
J Lipid Res; 1999 Jan; 40(1):1-16. PubMed ID: 9869645
[TBL] [Abstract][Full Text] [Related]
12. The low density lipoprotein receptor-related protein complexes with cell surface heparan sulfate proteoglycans to regulate proteoglycan-mediated lipoprotein catabolism.
Wilsie LC; Orlando RA
J Biol Chem; 2003 May; 278(18):15758-64. PubMed ID: 12598530
[TBL] [Abstract][Full Text] [Related]
13. The metabolism of triglyceride-rich lipoproteins revisited: new players, new insight.
Dallinga-Thie GM; Franssen R; Mooij HL; Visser ME; Hassing HC; Peelman F; Kastelein JJ; Péterfy M; Nieuwdorp M
Atherosclerosis; 2010 Jul; 211(1):1-8. PubMed ID: 20117784
[TBL] [Abstract][Full Text] [Related]
14. Disruption of autosomal recessive hypercholesterolemia gene shows different phenotype in vitro and in vivo.
Harada-Shiba M; Takagi A; Marutsuka K; Moriguchi S; Yagyu H; Ishibashi S; Asada Y; Yokoyama S
Circ Res; 2004 Oct; 95(9):945-52. PubMed ID: 15472122
[TBL] [Abstract][Full Text] [Related]
15. Chylomicron remnant uptake is regulated by the expression and function of heparan sulfate proteoglycan in hepatocytes.
Zeng BJ; Mortimer BC; Martins IJ; Seydel U; Redgrave TG
J Lipid Res; 1998 Apr; 39(4):845-60. PubMed ID: 9555948
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of hepatic chylomicron remnant clearance.
Willnow TE
Diabet Med; 1997 Aug; 14 Suppl 3():S75-80. PubMed ID: 9272618
[TBL] [Abstract][Full Text] [Related]
17. Heparan sulfate proteoglycans and triglyceride-rich lipoprotein metabolism.
Bishop JR; Stanford KI; Esko JD
Curr Opin Lipidol; 2008 Jun; 19(3):307-13. PubMed ID: 18460924
[TBL] [Abstract][Full Text] [Related]
18. Type 2 diabetes in mice induces hepatic overexpression of sulfatase 2, a novel factor that suppresses uptake of remnant lipoproteins.
Chen K; Liu ML; Schaffer L; Li M; Boden G; Wu X; Williams KJ
Hepatology; 2010 Dec; 52(6):1957-67. PubMed ID: 21049473
[TBL] [Abstract][Full Text] [Related]
19. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway.
Jong MC; Dahlmans VE; van Gorp PJ; van Dijk KW; Breuer ML; Hofker MH; Havekes LM
J Clin Invest; 1996 Nov; 98(10):2259-67. PubMed ID: 8941642
[TBL] [Abstract][Full Text] [Related]
20. Heparan sulfate proteoglycan/low density lipoprotein receptor-related protein pathway involved in type III hyperlipoproteinemia and Alzheimer's disease.
Mahley RW
Isr J Med Sci; 1996 Jun; 32(6):414-29. PubMed ID: 8682647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
